How many insider trades does FilingIQ track for AEON?

FilingIQ tracks 26 Form 4 insider transactions for AEON (AEON Biopharma, Inc.), covering filings from Jul 21, 2023 onwards. 8 of those were filed in the last 90 days.

Are AEON insiders net buyers or net sellers?

Across the full Form 4 history for AEON, 3 transactions (12%) were open-market purchases and 1 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does AEON insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is AEON in?

AEON Biopharma, Inc. (AEON) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.06M.

AEON insider trading

NYSE American Healthcare

AEON Biopharma, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

12% / 4%

Market cap

$26.06M

About AEON Biopharma, Inc.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Company website: www.aeonbiopharma.com

AEON insider activity at a glance

FilingIQ has scored 26 insider transactions for AEON since Jul 21, 2023. The most recent filing in our index is dated Apr 2, 2026.

Across the full history, 3 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on AEON insider trades is 61.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live AEON trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for AEON?: FilingIQ tracks 26 Form 4 insider transactions for AEON (AEON Biopharma, Inc.), covering filings from Jul 21, 2023 onwards. 8 of those were filed in the last 90 days.
Are AEON insiders net buyers or net sellers?: Across the full Form 4 history for AEON, 3 transactions (12%) were open-market purchases and 1 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does AEON insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is AEON in?: AEON Biopharma, Inc. (AEON) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.06M.

Methodology & sources

Every AEON insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.